SYSCO Corporation vs TransMedics Group Inc — how do they compare? SYSCO Corporation trades at $81.58 (market cap $39.08B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: SYSCO Corporation is far larger — about 13× TransMedics Group Inc's market cap, and SYSCO Corporation pays a 2.7% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SYY | TMDX | |
|---|---|---|
Market Cap | $39.08B | $3.00B |
Sector | Consumer Staples | Technology |
52-Week High | $91.16 | $150.42 |
52-Week Low | $69.30 | $61.99 |
Enterprise Value | $52.26B | $3.39B |
Dividend Yield | 2.7% | — |
Signals from Pluang's Aura AI — not financial advice
Sysco Corporation (SYY) trades at $79.84, down 0.26% with a bullish technical signal despite mixed moving averages. The company reported $81.37B in revenue for 2025 with a 2.08% net margin and maintains strong analyst support with 60% buy ratings. Recent news highlights AI efficiency initiatives and reaffirmed 2027 guidance, while the pending Jetro Restaurant Depot acquisition presents both growth opportunities and integration risks.
Sysco offers stable fundamentals with consistent revenue growth and dividend aristocrat status, but faces execution risks from its major acquisition and margin pressures. The stock trades below the $88.25 consensus target, suggesting potential upside if AI efficiency gains materialize and integration proceeds smoothly.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Trailing returns across standard periods
Latest headlines on both assets
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →